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Introduction: During the progression of rheumatoid arthritis (RA), there are frequent but intermittent flares in
which the joint becomes acutely inflamed and painful. Although a number of drug therapies are currently used to
treat RA, their effectiveness is variable and side effects are common. Endocannabinoids have the potential to
ameliorate joint pain and inflammation, but these beneficial effects are limited by their rapid degradation. One
enzyme responsible for endocannabinoid breakdown is fatty acid amide hydrolase (FAAH). The present study
examined whether URB597, a potent and selective FAAH inhibitor, could alter inflammation and pain in a mouse
model of acute synovitis.
Methods: Acute joint inflammation was induced in male C57BL/6 mice by intra-articular injection of 2% kaolin/2%
carrageenan. After 24 hr, articular leukocyte kinetics and blood flow were used as measures of inflammation, while
hindlimb weight bearing and von Frey hair algesiometry were used as measures of joint pain. The effects of local
URB597 administration were then determined in the presence or absence of either the cannabinoid (CB)1 receptor
antagonist AM251, or the CB2 receptor antagonist AM630.
Results: URB597 decreased leukocyte rolling and adhesion, as well as inflammation-induced hyperaemia. However,
these effects were only apparent at low doses and the effects of URB597 were absent at higher doses. In addition
to the anti-inflammatory effects of URB597, fatty acid amide hydrolase (FAAH) inhibition improved both hindlimb
weight bearing and von Frey hair withdrawal thresholds. The anti-inflammatory effects of URB597 on leukocyte
rolling and vascular perfusion were blocked by both CB1 and CB2 antagonism, while the effect on leukocyte adherence
was independent of cannabinoid receptor activation. The analgesic effects of URB597 were CB1 mediated.
Conclusions: These results suggest that the endocannabinoid system of the joint can be harnessed to decrease acute
inflammatory reactions and the concomitant pain associated with these episodes.Introduction
Rheumatoid arthritis (RA) is an inflammatory disorder
that is one of the leading causes of disability worldwide
[1]. Although the pathological presentation of RA can
vary between patients, a prominent characteristic of the
disease is the occurrence of acute inflammatory flares
with concomitant pain. During inflammatory flares,
blood flow is increased to the inflamed area and leuko-
cytes are recruited to the affected joint. These events
can lead to a potentiation of the inflammatory response;* Correspondence: jason.mcdougall@dal.ca
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stated.therefore, pharmacotherapeutics that decrease both the
synovitis and joint pain would be extremely beneficial
for the clinical management of RA.
During synovitis, pro-inflammatory molecules released
into the joint initiate local inflammatory vasodilatation
and increased vascular permeability [2]. The migration
of immune cells into inflamed tissues involves a multi-
step process, which requires biochemical interactions
between the leukocytes and the local microvasculature.
During inflammation, vascular endothelial cells begin to
express cell adhesion molecules (CAMs) that bind other
CAMs expressed on the surface of passing leukocytes.
These interactions initiate the capture of activated leu-
kocytes, which commence a rolling behaviour where theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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leukocyte velocity continues to decrease, these cells even-
tually stop and adhere to the intravascular wall. Finally,
adherent leukocytes are able to exit the blood vessels and
enter the surrounding tissue, where they can release vari-
ous mediators that influence local inflammation [3].
The number one concern of RA patients is safe and ef-
fective alleviation of the chronic pain that accompanies
the disease. During acute synovitis, algogenic mediators
are released from extravasated immune cells and primary
afferent nerve terminals. The accumulation of these pain-
causing agents within the joint leads to the sensitization of
mechanosensory nerves and the awakening of silent noci-
ceptors, such that even normal joint movements become
painful [4,5]. In the rat knee joint, inflammatory neuro-
peptides that have been shown to induce peripheral
sensitization and cause pain include substance P [6], vaso-
active intestinal peptide [7], nociceptin [8] and pituitary
adenylate cyclase-activating polypeptide [9]. Conversely,
very little is known regarding the activity of endogenous
analgesic mediators in joint tissues. The endogenous opi-
oid peptide endomorphin-1 was found to reduce periph-
eral sensitization in acutely inflamed rat knees [10], as well
as ameliorating joint inflammation [11]. The serine pro-
teinase cathepsin G has also been shown to reduce noci-
ception in normal rat knees [12].
Cannabinoids are a family of molecules related to the
biologically active components of Cannabis sativa, and
have the potential to alleviate both inflammation and pain
[13-15]. Cannabinoids are classified by their ability to acti-
vate cannabinoid type 1 (CB1) [16] and/or type 2 (CB2)
receptors. The cannabinoid system is a promising target
for treating arthritis because of the localization of CB1 re-
ceptors on joint primary afferents [17] and CB2 receptors
in the synovium [18]. In a rat model of osteoarthritis
(OA), articular CB1 receptor activation significantly de-
creased the nociceptor firing rate [19], while the CB2 re-
ceptor agonist GW405833 unexpectedly sensitized joint
afferents [18], although off-target drug effects may have
produced this latter response. Local administration of can-
nabinoids has also been found to increase synovial blood
flow [20], indicating that the synovial cannabinoid system
can increase joint inflammation. Although cannabinoids
were first discovered in plants (phytocannabinoids) [13],
recent research has uncovered several endogenous
cannabinoid molecules, the most well studied being N-
arachidonoylethanolamine (anandamide) [14,21]. Anan-
damide is known to be both anti-inflammatory [14] and
analgesic [15]; however, these beneficial effects are limited,
due to the rapid metabolism of anandamide by enzymes
like fatty acid amide hydrolase (FAAH) [22]. In addition to
anandamide, FAAH is also responsible for the metabolism
of other fatty acid amides like N-oleoylethanolamine (OEA)
and N-palmitoylethanolamine (PEA) [23]. Inhibiting FAAHincreases tissue anandamide levels in vivo [24], and FAAH
inhibitors are capable of decreasing pain in rodent models
of OA [25].
The current study aimed to test the effects of local
FAAH inhibition, using the potent and selective FAAH
inhibitor URB597, on blood flow, leukocyte trafficking
and pain in a mouse model of acute arthritic flares.
Methods
Animals
Male C57BL/6 mice (n =175; 21 to 32 g; six to eight weeks
old; Charles River Laboratories Inc., Senneville, QC,
Canada) were housed at 22 ± 2°C on a 12:12 hr light:dark
cycle (light-on from 7:00 to 19:00). Cages were lined with
woodchip bedding and animals were provided with envir-
onmental enrichment. Standard lab chow and water were
provided ad libitum. The experimental protocols were ap-
proved by the Dalhousie University Committee on Labora-
tory Animals, which acts in accordance with the standards
put forth by the Canadian Council for Animal Care.
Kaolin-carrageenan inflammation
All animals had an acute unilateral inflammation induced
by injection of kaolin and carrageenan into the right knee
joint. Animals were deeply anaesthetized (2 to 4% isoflur-
ane; 100% oxygen at 1 L/min) and an acceptable plane of
anaesthesia was confirmed by failure to produce a hind-
paw withdrawal reflex. The right knee was shaved and the
knee joint diameter was measured using a digital microm-
eter (Mituyoto Instruments, Tokyo, Japan). The knee area
was then swabbed with 100% ethanol and 10 μl of 2% kao-
lin was injected into the intra-articular space. The knee
was then manually extended and flexed for 10 min to dis-
perse the kaolin throughout the joint and irritate the syno-
vium. Next, 10 μl of 2% carrageenan was injected in the
same manner and was followed by 30 s of hindlimb
flexion and extension. Animals were returned to their
cages for 24 hr. Knee joint diameter was then reassessed
to confirm positive inflammation.
Surgical preparation for vascular assessment
The following preparation was conducted before intravi-
tal microscopy (IVM) and laser speckle contrast analysis
(LASCA) of the inflamed knee. Animals were anaesthe-
tized by an intraperitoneal injection of urethane (25% in
saline; 0.3 to 0.4 ml) and a surgical plane of anaesthesia
was confirmed by failure to elicit a hindpaw withdrawal
reflex. A longitudinal incision was made in the skin of the
neck to expose the trachea, left carotid artery and left
jugular vein, which were individually cannulated. PE-60
tubing was used for the tracheal cannulation while PE-10
tubing, filled with heparinized saline (1U/ml), was used for
the blood vessel cannulations. The capsular microcircula-
tion of the right knee was exposed by surgically removing
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wide), and the knee was immobilized. Physiological buffer
(37°C) was immediately and continuously perfused over
the exposed joint.
Intravital microscopy
IVM was used to assess leukocyte trafficking within the
microcirculation of the knee joint, as previously described
[26]. After surgical preparation, the synovial microcircula-
tion was visualized under incident fluorescent light using a
Leica DM2500 microscope with a HCX APO L 20X ob-
jective and a HC Plan 10X eyepiece (Leica Microsystems
Inc., Richmond Hill ON, Canada; final magnification
200X). In vivo leukocyte staining was achieved by intra-
venous administration of 0.05% rhodamine 6G (0.05 ml).
Straight, unbranched, postcapillary venules (15 to 50 μm
in diameter) overlying the knee capsule were selected for
visualization. Videos (1 min duration) of leukocyte kinetics
were captured using a BC-71 AVT camera (Horn Imaging,
Aalen, Germany).
Two measures of leukocyte-endothelial interactions
were used to assess inflammation: (i) number of rolling
leukocytes and (ii) number of adherent leukocytes per 50
μm of vessel. Rolling leukocytes were defined as rhoda-
mine 6G-stained cells travelling slower than the surround-
ing flow of blood in the vessel of interest. The rolling
leukocyte measure was obtained by counting the number
of rolling leukocytes per minute to pass an arbitrary line
perpendicular to the vessel of interest. Adherent leukocytes
were defined as rhodamine 6G-stained cells that remained
stationary for a minimum of 30 s. Total leukocyte adhe-
sion was quantified by counting the number of adherent
cells within a 50 μm portion of the vessel. A baseline
measure was first taken to observe leukocyte kinetics
before drug administration. Following this measure, ei-
ther vehicle, URB597 (0.3 to 30 mg/kg), URB597 (0.3
mg/kg) + AM251 (CB1 antagonist, 0.2 mg/kg) or URB597
(0.3 mg/kg) + AM630 (CB2 antagonist, 0.2 mg/kg) was ap-
plied directly over the exposed knee joint. Doses were
chosen based on effective dosing regimens as previously
reported [18-20,25]. For all URB597 + antagonist trials in
this study, the antagonists were administered 10 min be-
fore URB597. Antagonist alone control trials were also
conducted. Subsequent recordings were taken 5, 10, 20, 30
and 60 min after URB597 administration.
Laser speckle contrast analysis
In order to quantify microvascular perfusion, knee joint
blood flow was assessed using a PeriCam PSI System
(Perimed Inc., Ardmore, PA, USA). Recordings were taken
at a working distance of 10 cm with a frame rate of 25 im-
ages per second, which were then averaged to create one
perfusion image per second. Following a baseline record-
ing of 1 min, a 100 μl bolus of URB597 (0.3 to 30 mg/kg)was applied directly to the knee joint, with each dose be-
ing applied in separate cohorts of animals. The effect of
AM251 or AM630 (0.2 mg/kg) on URB597 perfusion re-
sponses was also tested in different groups of mice. Mean
perfusion (1 min sampling time) was measured at 5, 10,
20, 30 and 60 min following drug treatment. A dead scan
of the knee was taken post mortem and this value was sub-
tracted from all measurements to account for any optical
noise in the tissue.Hindlimb incapacitance
Mice were habituated to the hindlimb incapacitance testing
apparatus (Linton Instrumentation, Diss, UK) for three
consecutive days prior to baseline measurement. Weight
distribution measurements of one-second duration were
taken while the animal was standing on both hindlimbs,
with one hindpaw on each of the two force plates. Baseline
weight-bearing measurements were taken before and 24 hr
after induction of inflammation. Separate cohorts of mice
were then treated with either vehicle, URB597 (3 mg/kg),
URB597 (3 mg/kg) + AM251 (0.2 mg/kg), or URB597
(3 mg/kg) + AM630 (0.2 mg/kg), applied subcutaneously
(s.c.) over the inflamed knee joint, or URB597 (3 mg/kg)
applied s.c. over the contralateral knee joint. Test mea-
surements (average of six measures per time point) were
then taken at 30, 60, 90 and 180 min following drug
administration.von Frey hair mechanosensitivity
The same animals underwent concurrent secondary allody-
nia testing as a behavioural measure of referred pain. Ipsi-
lateral hindpaw mechanosensitivity was assessed by plantar
application of von Frey hair filaments using a modification
of the Dixon up-and-down method [27]. Animals were
placed in elevated Plexiglas chambers on metal mesh floor-
ing allowing access to the paws. After allowing the animal
to acclimate until exploratory behaviour ceased, a von Frey
hair was applied perpendicular to the plantar surface of the
hindpaw (avoiding the toe pads) until the hair just bent,
and the hair was held in place for three seconds. If there
was a positive response (that is withdrawal, shake or lick of
the hindpaw), the next lower strength hair was applied; if
there was no response, the next higher strength hair was
applied up to a maximum cutoff level, which corresponded
to a 4 g bending force. After the first difference in response
was observed, four more measurements were made and the
pattern of responses were converted to a 50% withdrawal
threshold calculated using the following formula: 10[Xf+kδ]/
10,000; where Xf = value (in log units) of the final von Frey
hair used, k = tabular value for the pattern of the last six
positive/negative responses, and δ =mean difference (in log
units) between stimuli. A time course at 30, 60, 90 and 180
min following drug administration was constructed.
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URB597 (FAAH inhibitor; [3-(3-carbamoylphenyl)phenyl]
N-cyclohexylcarbamate), AM251 (CB1 receptor antagonist;
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piper-
idin-1-ylpyrazole-3-carboxamide) and AM630 (CB2 recep-
tor antagonist; 6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)
indol-3-yl]-(4-methoxyphenyl)methanone) were obtained
from Cayman Chemicals (Ann Arbor, MI, USA). Rhoda-
mine 6G, cremophor, dimethyl sulphoxide (DMSO), ur-
ethane, carrageenan and kaolin were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Solutions of URB597
(0.3 to 30 mg/kg), AM251 (0.2 mg/kg) and AM630 (0.2
mg/kg) were prepared in vehicle (1:1:8; DMSO:cremophor:
saline) on the day of use. Rhodamine 6G (0.05%) was dis-
solved in saline. Physiological buffer (135 mM NaCl, 20
mM NaHCO3, 5 mM KCl, 1 mM MgSO4*7H2O, pH =7.4)
was prepared in house. Solutions of carrageenan (2%) and
kaolin (2%) were dissolved in saline and stored at 4°C.
Statistical analysis
Data conformed to a Gaussian distribution (Kolmogrov-
Smirnov normality test) and were, therefore, tested with
parametric statistics. For the IVM and LASCA experi-
ments, time-course data were analyzed using a two-way
analysis of variance (ANOVA), with time and drug
treatment as the variables. The time at which URB597
had the greatest effect, when compared to vehicle, was
selected and further analysis focused on this time point.
For the dose-response profiles, groups of data were
compared against vehicle using a one-way ANOVA
with a Dunnett’s post hoc test. All other analysis of
drug effects were compared to URB597 using a one-
way ANOVA with a Bonferroni correction. Knee diameter
data were analyzed by a paired two-tailed Student’s t test.
A P value <0.05 was considered statistically significant.
Data are expressed as means ± standard error of the mean
(SEM).Results
Knee diameter
To ensure adequate inflammation, knee joint diameter
was measured before and 24 hr after kaolin/carrageenan
injection. Kaolin/carrageenan inflammation resulted in an
average of 0.60 ± 0.02 mm (15.5%) increase in knee diam-
eter 24 hr post injection (3.71 ± 0.01 mm before; 4.31 ±
0.02 mm after; P <0.0001; n =175).Mean arterial pressure
During IVM and LASCA measurements, mean arterial
pressure did not change in response to drug administra-
tion and was found to be comparable between all experi-
mental groups.Leukocyte trafficking
Over the course of one hour, URB597 (0.3 mg/kg) signifi-
cantly decreased leukocyte rolling when compared to ve-
hicle (P <0.0001; n =7 to 11; Figures 1 and 2A). The most
robust effect was observed 20 min after administration;
therefore all subsequent measurements focused on this
time point. Low-dose URB597 (0.3 mg/kg) caused an aver-
age of 68.0 ± 6.8% (n =11) decrease in leukocyte rolling 20
min after administration (Figure 2B). This inhibition of
rolling was significantly different from vehicle-treated ani-
mals (P <0.001; n =7 to 11; Figure 2B) and was blocked by
both AM251 and AM630 (P <0.01; n =6; Figure 3A).
Interestingly, higher doses of URB597 (3 to 30 mg/kg) had
no inhibitory effect on leukocyte rolling (Figure 2B).
At 20 min, URB597 (0.3 and 3.0 mg/kg) also signifi-
cantly decreased the number of adherent leukocytes com-
pared to vehicle (P <0.05; n =6; Figure 2C). Higher doses
of URB597 (10 to 30 mg/kg), however, were less effective
(n =5 to 6; Figure 2C). The inhibitory effect of URB597
(0.3 mg/kg) on leukocyte adhesion was not blocked by
AM251 (P >0.05; n =6; Figure 3B) nor AM630 pretreat-
ment (P >0.05; n =6; Figure 3B).
When administered alone, neither antagonist had any
effect on leukocyte rolling or adherence, when compared
to vehicle (P >0.05; n =6 to 7; data not shown).
Microvascular perfusion
Local administration of URB597 (3.0 mg/kg) decreased
microvascular perfusion, when compared to vehicle treat-
ment (P <0.01; n =6 to 10; Figure 4A). This effect was
most prominent at 20 min, where URB397 (3.0 mg/kg) de-
creased microvascular perfusion by an average of 19.6 ±
3.6% (n =7; Figure 4B). The inhibitory effect of URB597
on joint hyperaemia was blocked by both AM251 and
AM630 (P <0.05; n =6 to 10; Figure 4C). High-dose
URB597 (10 to 30 mg/kg) was ineffective at reducing in-
flamed joint hyperaemia (n =5 to 7; Figure 4B).
Hindlimb weight bearing
Based on the results of the inflammation studies, a dose of
3.0 mg/kg was chosen for pain behaviour assessment.
URB597 significantly improved inflamed hindlimb weight
bearing during the initial 3 hr after administration (P <0.05;
n =12; Figure 5A). The most profound effect of URB597
was observed at 30 min; therefore, subsequent experiments
focused on this time point. In mice pretreated with the
CB1 receptor antagonist AM251 (0.2 mg/kg; n =9), the
anti-nociceptive effect of URB597 was abolished (P <0.05;
Figure 5B). Conversely, pretreatment with the CB2 receptor
antagonist AM630 (0.2 mg/kg; n =9) had no effect on
URB597-induced anti-nociception (P >0.05; Figure 5B). In
order to confirm that FAAH inhibition was occurring lo-
cally in the treated joint and not systemically, URB597 (3.0
mg/kg) was administered to the contralateral joint and, in
Figure 1 Intravital microscopy images showing circulating leukocytes in the anteromedial aspect of acutely inflamed mouse knees in response
to either (A) vehicle or (B) the FAAH inhibitor URB597. Arrows indicate stained leukocytes. Scale bar =50 μm. FAAH, fatty acid amide hydrolase.
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(P >0.05; n =9; Figure 5B).
When administered alone, neither antagonist had an
effect on hindlimb weight bearing when compared to ve-
hicle (P >0.05; n =6 to 7; data not shown).
von Frey hair secondary allodynia
Over the course of 1 hr, URB597 (3.0 mg/kg) signifi-
cantly increased paw withdrawal thresholds when com-
pared to vehicle (P <0.05; two-way ANOVA; n =12 to
14; Figure 6A). Paw withdrawal thresholds returned to
baseline after 2 to 3 hrs; therefore, further experiments
focused on the 1 hr time point. The anti-allodynic effect
of URB597 was blocked by pretreatment with the CB1
receptor antagonist AM251 (P <0.05; n =11; Figure 6B),
but not the CB2 receptor antagonist AM630 (P >0.05;
n =13; Figure 6B). When URB597 was administered to
the contralateral knee, the anti-allodynic effect of the
FAAH inhibitor was negligible (Figure 6B).
Discussion
The medicinal value of Cannabis sativa has been known
for thousands of years [28]; however, scientists have only
begun to uncover the endogenous mechanisms that under-
lie these beneficial effects. Based on the results presented
here, the endocannabinoid system is capable of decreasing
joint hyperaemia, leukocyte trafficking and pain during
acute inflammatory events.
The effects of URB597 on inflammation
Activation of the endocannabinoid system has been
shown to decrease the development of inflammation in
the intestine [29], central nervous system (CNS) [30]
and hindpaw [31]. More specifically, cannabinoids arecapable of reducing leukocyte proliferation and cytokine
release [32,33]. In our study, inflammation was mea-
sured in vivo by visualizing the interactions between leu-
kocytes and the vascular endothelium, as well as
measuring changes in vascular perfusion in acutely in-
flamed mouse knee joints. When kaolin/carrageenan-in-
flamed knee joints were treated with low-dose URB597,
there was a significant reduction in the number of roll-
ing and adherent leukocytes, and inflammation-induced
hyperaemia. A similar effect has been observed in the
cerebral [34,35] and ocular [36] microcirculation, where
synthetic cannabinoids decreased leukocyte rolling and
adhesion. However, as dosing increased, the effects of
URB597 on leukocyte kinetics and hyperaemia were less
pronounced. One possible explanation for this effect is
the downregulation and/or desensitization of articular
cannabinoid receptors as a result of excessive endocan-
nabinoid accumulation in the joint [37]. Alternatively,
high doses of URB597 may be having off-target effects,
which promote inflammation and pain thereby masking
any beneficial responses. For example, high concentra-
tions of anandamide are known to cause peripheral
sensitization in joints by opening vanilloid-gated ion
channels [38]. Furthermore, anandamide can be oxy-
genated via a cyclooxygenase-2 pathway leading to the
formation of pro-inflammatory and algesic prostamides,
which may offset the therapeutic benefits of FAAH in-
hibition [39,40]. Therefore, URB597 may need to be ad-
ministered with selective prostamide antagonists in
order to achieve greater pain relief and resolution of
inflammation.
In the present study, the inhibitory effects of URB597
on leukocyte rolling and blood flow were blocked by both
CB1 and CB2 receptor antagonism, while the reduction in
Figure 2 (See legend on next page.)
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Figure 2 The effects of URB597 on leukocyte trafficking in the inflamed knee. (A) Time course of the effect of locally administered URB597
(closed circles) vs. vehicle (open circles) on leukocyte rolling. There was a significant reduction in the number of rolling leukocytes after URB597
administration, when compared to vehicle (P <0.0001; two-way ANOVA; n =7 to 11). (B) Dose-response profile of the effect of URB597 on
leukocyte rolling 20 min after administration. URB597 (0.3 mg/kg) significantly decreased leukocyte rolling, when compared to vehicle, but this
effect was diminished at higher doses. (C) Dose-response profile for the effects of URB597 on leukocyte adhesion 20mins after administration.
URB597 (0.3 and 3.0 mg/kg) significantly inhibited leukocyte adhesion, when compared to vehicle; however, this effect was attenuated at higher
doses. Data are means ± SEM. *P <0.05, **P <0.01, ***P <0.001 one-way ANOVA with Dunnett’s post hoc test vs. vehicle; n =5 to 11. ANOVA, analysis
of variance; SEM, standard error of the mean.
Figure 3 The contribution of cannabinoid receptors to the effects of URB597 on leukocyte trafficking in the inflamed knee. (A) Number
of rolling leukocytes per minute 20 min after administration of URB597 (0.3 mg/kg) to acutely inflamed knees. Local application of the drug
significantly decreased the number of rolling leukocytes and this effect was blocked by local pretreatment with the CB1 receptor antagonist
AM251 (0.2 mg/kg) and the CB2 receptor antagonist AM630 (0.2 mg/kg). (B) Number of adherent leukocytes per 50 μm of vessel 20 min after
URB597 administration. Leukocyte adhesion was significantly reduced by URB597 administration and this effect was not blocked by either
cannabinoid receptor antagonist. Data are means ± SEM. *P <0.05, one-way ANOVA with Bonferroni’s post hoc test vs. URB597 (0.3 mg/kg); n =6
to 11. ANOVA, analysis of variance; SEM, standard error of the mean.
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Figure 4 Laser speckle contrast analysis of the inflamed
mouse knee joint. (A) Time course of the effect of locally
administered URB597 (closed circles) vs. vehicle (open circles) on
vascular perfusion. There was a significant reduction in local blood
flow after URB597 administration, when compared to vehicle.
P <0.0001; two-way ANOVA; n =6 to 7. (B) Dose-response profile for
the effects of URB597 20 mins after administration. Local blood flow
was significantly reduced by only low-dose URB597 (3.0 mg/kg).
**P <0.01 one-way ANOVA with Dunnett’s post hoc test vs. vehicle;
n =5 to 7. (C) Both AM251 (0.2 mg/kg) and AM630 (0.2 mg/kg)
blocked the effect of URB597 (3.0 mg/kg) on blood flow in the
inflamed mouse knee joint. Data are means ± SEM.*P <0.05,
one-way ANOVA with Bonferroni’s post hoc test vs. URB597
3.0 mg/kg; n =6 to 8. ANOVA, analysis of variance; SEM, standard
error of the mean.
Krustev et al. Arthritis Research & Therapy 2014, 16:437 Page 8 of 12
http://arthritis-research.com/content/16/5/437leukocyte adhesion was CB receptor independent. The
inhibitory effect of URB597 on inflammation could be
due to a decrease in joint nerve activity following CB1
receptor activation. It has been shown that CB1 receptors
are highly expressed on knee joint nerve terminals [17] and
that selective activation of CB1 receptors can cause a de-
crease in the neuronal release of pro-inflammatory neuro-
peptides, such as calcitonin gene-related peptide (CGRP)
[41]. Since CGRP promotes leukocyte migration [42] and
vasodilatation [43], it is possible that the anti-inflammatory
effects of URB597 described here are due to a CB1
receptor-dependent reduction in CGRP release although
other pro-inflammatory neurogenic factors could also be
involved.
The present investigation found that CB2 receptors are
involved in endocannabinoid-mediated inhibition of roll-
ing and hyperaemia in inflamed joints. This CB2-mediated
inhibitory effect on leukocyte rolling has previously been
observed in the retina [44]. The CB2 receptor agonist
JWH-133 has been shown to inhibit the expression of P-
selectin [44], an adhesion molecule responsible for the ini-
tiation and maintenance of leukocyte rolling [3]. It is,
therefore, possible that URB597 decreased leukocyte roll-
ing by promoting the inhibitory effect of the endocannabi-
noid system on selectin expression.
The inability of CB receptor antagonists to block the
inhibitory effects of URB597 on leukocyte adhesion is in-
triguing. While cannabinoids classically bind to either CB1
or CB2 receptors, atypical cannabinoids have been found to
bind to alternate G protein-coupled receptors such as
GPR55 and GPR18 [45]. Both of these receptors have been
found to have immunoregulatory functions [46] and, in the
brain, GPR18 stimulation has been shown to inhibit
leukocyte recruitment [47]. It is, therefore, possible that
URB597 is causing the accumulation of atypical endocan-
nabinoids in the joint whose activity reduces leukocyte ad-
hesion through either or both of these atypical cannabinoid
receptor subtypes.
The changes described here, concerning leukocyte adhe-
sion, are in contrast to a study by Ni and colleagues [35],
who found that cannabinoid-mediated leukocyte anti-
adhesion was CB2 receptor-dependent and the inhibitory
effect on leukocyte rolling was CB1 receptor-independent.
The reason for the disparity between the two studies could
be that Ni et al. were investigating leukocyte changes in re-
sponse to a non-selective CB receptor agonist (WIN5512-
2) and activity was assessed in the brain. Thus, there may
be subtle differences in cannabinoid receptor properties be-
tween the microcirculation of the CNS versus peripheral
tissues.
The anti-nociceptive effects of URB597
The results presented here show that URB597 can de-
crease inflammatory pain, and are in accordance with
Figure 5 Hindlimb weight bearing in mice with acute experimental joint inflammation. (A) Time course of the effects of URB597 (3.0 mg/kg) on
inflamed hindlimb weight bearing (baseline (BL) values represent pre-inflammation induction). Over the course of 3 hr, URB597 significantly improved
hindlimb weight bearing when compared to vehicle. P <0.0001; two-way ANOVA; n =12. (B) Hindlimb incapacitance 30 minutes after local administration
of URB597 to acutely inflamed knees. The anti-nociceptive effect of URB597 (3.0 mg/kg) was blocked by the CB1 receptor antagonist AM251 (0.2 mg/kg),
but not the CB2 receptor antagonist AM630 (0.2 mg/kg). When URB597 was administered to the contralateral knee, there was no observable effect on
hindlimb weight bearing. Data are means ± SEM. *P <0.05, **P <0.01; one-way ANOVA with Bonferroni’s post hoc test; n =9 to 14. ANOVA, analysis of
variance; SEM, standard error of the mean.
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cannabinoids in treating pain. The attenuation of hind-
limb incapacitance suggests that URB597 is having a
direct effect on functional pain recovery in the joint,
while the improvement in paw withdrawal threshold is
indicative of a reduction in referred pain (secondary allo-
dynia). Systemic FAAH inhibition has been shown to de-
crease animal pain behaviours in a preclinical model ofOA [25]. However, when URB597 was administered lo-
cally to the joint, it reduced nociceptor activity, suggesting
a peripheral site of action of endocannabinoids [25]. Since
contralateral administration of URB597 had no discernible
effect on hindlimb incapacitance and anti-allodynia here,
it can be inferred that the anti-nociceptive effects of
FAAH inhibition are locally mediated. The potential ad-
vantage of using URB597 peripherally is that it could allow
Figure 6 von Frey hair algesiometry in mice with acute joint inflammation. (A) Time course of the effects of URB597 (3.0 mg/kg) on
inflamed hindlimb von Frey withdrawal threshold. URB597 significantly improved hindlimb withdrawal thresholds when compared to vehicle.
P <0.0001; two-way ANOVA; n =12 to 14. (B) Inflammation-induced secondary allodynia 60 minutes after local administration of URB597 (3.0 mg/kg), as
tested by von Frey hair algesiometry. URB597 significantly improved mechanosensitivity. This effect was blocked by AM251 (0.2 mg/kg), but not AM630
(0.2 mg/kg). Contralateral administration of URB597 had a negligible effect on ipsilateral tactile sensitivity. Data are means ± SEM. *P <0.05, **P <0.01;
one-way ANOVA with Bonferroni’s post hoc test; n =9 to 14. ANOVA, analysis of variance; SEM, standard error of the mean.
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affected joints and avoid the potential psychotropic side
effects of cannabinoid receptor activation in the CNS.
The analgesic effects of URB597 were blocked by a CB1
antagonist, and this result corroborates other reports of
CB1 receptor-mediated analgesia [48]. The analgesic ef-
fects of CB1 receptor activation are thought to primarily
involve spinal [49] and supraspinal [50] CB1 receptors. Al-
though cannabinoids can reduce pain responses via the ac-
tivation of CB1 receptors in these higher centres, the datapresented in this study would suggest that peripheral
CB1 receptors are also able to elicit an anti-nociceptive
effect in joints. This hypothesis is supported by the obser-
vation that the selective CB1 receptor agonist arachidonyl-
2′-chloroethylamide (ACEA) significantly decreased the
nociceptor firing rate when applied locally to OA knee
joints [19].
While the preclinical evidence supporting the thera-
peutic potential of the endocannabinoid system is com-
pelling, a recent clinical trial involving OA patients was
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FAAH inhibitor PF-04457845 failed to improve reported
pain scores when compared to placebo. One of the dispar-
ities of this study compared to the preclinical findings is
that PF-04457845 was given systemically rather than
locally into the joint and as such could be imparting off-
target effects, particularly in the brain. In addition, the pa-
tients used in the trial were from a heterogeneous OA
population and were not stratified based on the degree of
synovitis, neuropathic involvement, or disease severity.
The data presented here indicate that FAAH inhibitors
may be more efficacious in OA patients who suffer from
acute inflammatory flares and ongoing synovitis.
Conclusions
In summary, the potent and selective FAAH inhibitor
URB597 was shown to have both anti-nociceptive and
anti-inflammatory effects in the kaolin/carrageenan model
of joint acute inflammation. These effects were local and
appear to be mediated by distinct cannabinoid receptor
mechanisms. Since FAAH breaks down several fatty acid
amides including anandamide, OAE and PEA, future work
is required to identify the specific endocannabinoids respon-
sible for reducing acute synovitis and pain. Nevertheless,
pharmacological promotion of endocannabinoid activity
could be a useful way to treat inflammatory joint flares.
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